PMID- 29296332
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2156-4639 (Print)
IS  - 2156-4647 (Electronic)
VI  - 1
IP  - 4
DP  - 2012
TI  - Clinical outcomes following image-guided stereotactic body radiation for 
      pulmonary oligometastases.
PG  - 317-325
AB  - ACKNOWLEDGEMENT AND FUNDING: This work was made possible by funding from NIH 
      grant T32 RR023254; Salary support for Dr M.M. Fuster was provided by the 
      Department of Veterans Affairs (BLR&D CDTA Career Development Award). KEYWORDS: 
      Pulmonary metastases; oligometastases; stereotactic body radiotherapy (SBRT); 
      frameless SBRT. BACKGROUND: Lung is a common site of extracranial metastases. 
      Frameless Stereotactic Body Radiation Therapy (SBRT) is a promising new therapy 
      for unresectable neoplastic lung lesions used at our institution. METHODS: A 
      retrospective study of 21 patients and 33 lesions treated with SBRT was done. 
      Local control (LC), distant control (DC), progression-free survival (PFS) and 
      overall survival (OS) were analyzed using the Kaplan-Meier method. Potential 
      prognostic factors were analyzed using the log-rank test and Cox regression. 
      Toxicities were also reported. RESULTS: Actuarial local control rates by lesions 
      were 88% (95% confidence interval [CI], 77-99%) and 76% (95% CI, 59-92%) at 
      12-and 24-months, respectively. Actuarial local control rates by patients was 80% 
      (95% CI, 62-98%) and 71% (95% CI, 43-100%) for 12- and 24-months, respectively. 
      DC rates were 52% (95% CI 31-74%) and 38% (95% CI, 15-61%), at 12- and 24-months 
      respectively. PFS rates were 52% (95% CI 31-74%) and 32% (95% CI 9-55%) at 12- 
      and 24-months, respectively. Overall survival rates were 90% (95% CI 77-100%) and 
      78% (95% CI 59-97%) at 12- and 24-months, respectively. Single metastasis was 
      associated with better PFS (p=0.023). No toxicities greater than CTCAE grade 3 
      were observed. CONCLUSIONS: Frameless SBRT achieves acceptable control in 
      pulmonary metastatic lesions with an excellent toxicity profile.
FAU - Kim, Daniel
AU  - Kim D
AD  - Department of Medicine, Division of Hematology and Oncology.
AD  - VA San Diego Healthcare System.
FAU - Fuster, Mark M
AU  - Fuster MM
AD  - VA San Diego Healthcare System.
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine; 
      University of California San Diego, La Jolla, CA.
FAU - Nath, Sameer K
AU  - Nath SK
AD  - Department of Medicine, Division of Hematology and Oncology.
AD  - Center for Advanced Radiotherapy Technologies.
FAU - Bharne, Anjali
AU  - Bharne A
AD  - Department of Medicine, Division of Hematology and Oncology.
FAU - Read, William
AU  - Read W
AD  - Department of Medicine, Division of Hematology and Oncology.
FAU - Bazhenova, Lyudmilla
AU  - Bazhenova L
AD  - Department of Medicine, Division of Hematology and Oncology.
FAU - Song, William Y
AU  - Song WY
AD  - Department of Medicine, Division of Hematology and Oncology.
AD  - Center for Advanced Radiotherapy Technologies.
FAU - Mundt, Arno J
AU  - Mundt AJ
AD  - Department of Medicine, Division of Hematology and Oncology.
AD  - Center for Advanced Radiotherapy Technologies.
FAU - Sandhu, Ajay P
AU  - Sandhu AP
AD  - Department of Medicine, Division of Hematology and Oncology.
AD  - Department of Radiation Oncology, Moores UCSD Cancer Center.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Radiosurg SBRT
JT  - Journal of radiosurgery and SBRT
JID - 101565296
PMC - PMC5658866
EDAT- 2012/01/01 00:00
MHDA- 2012/01/01 00:01
PMCR- 2012/01/01
CRDT- 2018/01/04 06:00
PHST- 2018/01/04 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2012/01/01 00:01 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - RSBRT-1-325 [pii]
PST - ppublish
SO  - J Radiosurg SBRT. 2012;1(4):317-325.